AKD’s Top 3 Pharma Picks For 2026
Introduction Pakistan’s pharmaceutical sector is entering 2026 with stronger earnings visibility, improving pricing flexibility, and rising focus on high-margin product categories. Companies with dominant brands, export...
Pakistan’s Pharma Sector: Mixed Results in April–June 2025
The April–June 2025 (2QCY25) results are out for Pakistan’s pharmaceutical sector, and the picture is mixed. Some companies delivered strong growth, while others struggled with...
Haleon Pakistan Limited (HALEON): Growth Boost from New Launches and Lower Costs
Haleon Pakistan Limited (HALEON), the well-known consumer healthcare company, is on track for a strong performance in 2QCY25. The company is expected to post earnings...
Are Pharma Stocks in Pakistan Poised for a Rerating?
After years of navigating tight price controls, rising costs, and volatile exchange rates, Pakistan’s pharmaceutical sector appears to be at a critical inflection point. Thanks...
Why pharma exports could be Pakistan’s next billion-dollar opportunity?
Pakistan’s pharmaceutical industry has been on an upward trajectory thanks to deregulation, margin expansion, and a rising domestic market. But a far less discussed, and...
Pharma Stock Valuations Are at a Discount, Is Now the Time to Buy?
Pakistan’s pharmaceutical sector has quietly morphed into a compelling value play. Despite major regulatory relief, margin expansion, and earnings growth, valuations across the board remain...
Can Pakistan’s local drugmakers outperform multinationals?
Pakistan’s pharmaceutical sector has entered a phase of structural transformation, and one question stands out: Can local drug manufacturers truly outperform multinational companies (MNCs)? Based...
Is Haleon stock ready to soar on new Panadol variants?
In Pakistan’s evolving pharmaceutical landscape, few brands hold as dominant a position as Panadol. Now, Haleon Pakistan Ltd (HALEON) is doubling down on this flagship...